TY - JOUR
AB - Inpharma 1331 - 30 Mar 2002 Inhaled fluticasone propionate suppresses adrenal function Inhaled fluticasone propionate suppresses adrenal function in paediatric patients, report researchers from the US. In their study, 62 paediatric patients (mean age of 11.6 years) with moderate-to-severe asthma received inhaled fluticasone propionate 176–1320 µg/day, administered by a metered dose inhaler with a spacer device. After the fluticasone propionate dosage had been constant for ≥ 3 months, patients were assessed for hypopituitary adrenal function. Patients with an abnormal morning cortisol level (< 5.5 µg/dl) had their study dosage halved or were switched to another inhaled corticosteroid. Cortisol levels reduced After a mean treatment duration of 8 months, fluticasone propionate therapy was associated with abnormal morning cortisol levels in 36% of patients. 43% of high-dose recipients (≥ 880 µg/day), compared with 17% of low-dose recipients (176 µg/day) had abnormal morning cortisol levels. Of 22 patients with an initial abnormal morning cortisol level, 17 underwent a second morning cortisol assessment after treatment was changed. 13 (77%) patients had a normal morning cortisol level on the second test. According to a stratified analysis of the difference in morning cortisol levels prior to and after the switch in 19 patients with abnormal 
TI - Inhaled fluticasone propionate suppresses adrenal function
JF - Inpharma Weekly
DO - 10.2165/00128413-200213310-00050
DA - 2013-02-09
UR - https://www.deepdyve.com/lp/springer-journals/inhaled-fluticasone-propionate-suppresses-adrenal-function-XScBgRgfXf
SP - 20
EP - 20
VL - 1331
IS - 1
DP - DeepDyve
ER -